Journal article
Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety
W Hiddemann, AM Barbui, MA Canales, PK Cannell, GP Collins, J Dürig, R Forstpointner, M Herold, M Hertzberg, M Klanova, J Radford, JF Seymour, K Tobinai, J Trotman, A Burciu, G Fingerle-Rowson, M Wolbers, T Nielsen, RE Marcus
Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
Abstract
Purpose The GALLIUM study (ClinicalTrials.gov identifier: NCT01332968) showed that obinutuzumab (GA101; G) significantly prolonged progression-free survival (PFS) in previously untreated patients with follicular lymphoma relative to rituximab (R) when combined with cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P; CHOP); CVP; or bendamustine. This report focuses on the impact of chemotherapy backbone on efficacy and safety. Patients and Methods A total of 1,202 patients with previously untreated follicular lymphoma (grades 1 to 3a), advanced disease (stage III or IV, or stage II with tumor diameter ≥ 7 cm), Eastern Cooperative Oncology Group performance status 0 to 2, an..
View full abstractGrants
Funding Acknowledgements
GALLIUM was sponsored by F. Hoffmann-La Roche. G.P.C. was supported by the Blood Theme of the Oxford National Institute for Health Research Biomedical Research Centre. Third-party medical writing assistance was funded by F. Hoffmann-La Roche.